Roivant Sciences Ltd.ROIVEarnings & Financial Report
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Revenue
$-39.6M
Gross Profit
N/A
Operating Profit
$-267.0M
Net Profit
$-206.5M
Gross Margin
N/A
Operating Margin
674.8%
Net Margin
521.8%
YoY Growth
-236.8%
EPS
$-0.28
Roivant Sciences Ltd. Q4 FY2025 Financial Summary
Roivant Sciences Ltd. reported revenue of $-39.6M (down 236.8% YoY) for Q4 FY2025, with a net profit of $-206.5M (down 36.6% YoY) (521.8% margin).
Key Financial Metrics
| Total Revenue | $-39.6M |
|---|---|
| Net Profit | $-206.5M |
| Gross Margin | N/A |
| Operating Margin | 674.8% |
| Report Period | Q4 FY2025 |
Roivant Sciences Ltd. Annual Revenue by Year
Roivant Sciences Ltd. annual revenue history includes year-by-year totals (for example, 2025 revenue was $-18.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $-18.1M |
| 2024 | $124.8M |
| 2023 | $31.5M |
| 2022 | $55.3M |
Roivant Sciences Ltd. Quarterly Revenue & Net Profit History
Roivant Sciences Ltd. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $2.0M | -77.8% | $-265.9M | -13301.2% |
| Q2 FY2026 | $1.6M | -64.9% | $-113.5M | -7225.9% |
| Q1 FY2026 | $2.2M | -72.8% | $-223.4M | -10292.9% |
| Q4 FY2025 | $-39.6M | -236.8% | $-206.5M | 521.8% |
| Q3 FY2025 | $9.0M | -75.7% | $169.4M | 1878.3% |
| Q2 FY2025 | $4.5M | +22.7% | $-230.2M | -5143.8% |
| Q1 FY2025 | $8.0M | -63.1% | $95.3M | 1192.7% |
| Q4 FY2024 | $28.9M | +5.7% | $-151.1M | -522.3% |
Income Statement
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.9M | $8.0M | $4.5M | $9.0M | $-39.6M | $2.2M | $1.6M | $2.0M |
| YoY Growth | 5.7% | -63.1% | 22.7% | -75.7% | -236.8% | -72.8% | -64.9% | -77.8% |
Balance Sheet
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.22B | $6.50B | $6.21B | $5.79B | $5.44B | $5.03B | $5.06B | $5.23B |
| Liabilities | $774.0M | $601.2M | $626.0M | $256.4M | $249.7M | $216.7M | $257.1M | $251.1M |
| Equity | $5.97B | $5.44B | $5.15B | $5.19B | $4.69B | $4.35B | $4.36B | $4.27B |
Cash Flow
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-108.5M | $-192.8M | $-266.8M | $-207.3M | $-172.6M | $-204.4M | $-185.7M | $-196.5M |